Sirnaomics, Inc., a Gaithersburg, Md.-based biopharmaceutical company in development of RNAi therapeutics, closed $25m Series C1 financing.
The round was led by Yuexiu New Industrial Investment, followed by Sangel Biomedical Venture Capital, HuaKong Equity Investment and Qianhai Shenghui Investment.
The proceeds will be used to expand the clinical programs of the lead anti-fibrosis and anti-cancer RNAi therapeutics, strengthen the management team to support growth and bolster the company pre-clinical development of new drug candidates.
Led by Founder and CEO Dr. Patrick Y. Lu, and Dr. Michael Molyneaux, Chief Medical Officer, Sirnaomics is a biopharmaceutical company for discovery and development of RNAi therapeutics.
A Delaware corporation headquartered in Gaithersburg, Maryland, USA, with subsidiaries in Suzhou and Guangzhou, China, the company is advancing its proprietary technologies using pluripotent siRNA cocktail design and nanoparticle-enhanced therapeutic delivery to treat critical human diseases.
Sirnaomics’ STP705 is an siRNA (small interfering RNA) therapeutic candidate targeting TGF-β1 and COX-2. STP705 takes advantage of a dual-targeted inhibitory property and PNP-enhanced delivery to directly impact tissue fibrotic activity as well as inhibit tumor activity. The product has been validated in preclinical models and has demonstrated both anti-fibrotic activity and anti-tumor. The product has a fully-developed validated manufacturing process and the pre-clinical safety profile for STP705 supports its use in human clinical studies with a broad application potential.
STP705 is currently under a Phase IIa clinical study for Hypertrophic Scar (HTS) treatment in USA, and the same indication has also been approved for clinical study by Chinese FDA.